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The Enduring Importance of Animal Models in Understanding Periodontal
Disease
Abstract
Whereas no single animal model can reproduce the complexity of periodontitis, different aspects of the
disease can be addressed by distinct models. Despite their limitations, animal models are essential for
testing the biological significance of in vitro findings and for establishing cause-and-effect relationships
relevant to clinical observations, which are typically correlative. We provide evidence that animal-based
studies have generated a durable framework for dissecting the mechanistic basis of periodontitis. These
studies have solidified the etiologic role of bacteria in initiating the inflammatory response that leads to
periodontal bone loss and have identified key mediators (IL-1, TNF, prostaglandins, complement, RANKL)
that induce inflammatory breakdown. Moreover, animal studies suggest that dysbiosis, rather than
individual bacterial species, are important in initiating periodontal bone loss and have introduced the
concept that organisms previously considered commensals can play important roles as accessory
pathogens or pathobionts. These studies have also provided insight as to how systemic conditions, such
as diabetes or leukocyte adhesion deficiency, contribute to tissue destruction. In addition, animal studies
have identified and been useful in testing therapeutic targets.
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Whereas no single animal model can reproduce the
complexity of periodontitis, different aspects of the disease
can be addressed by distinct models. Despite their limitations,
animal models are essential for testing the biological
signiﬁcance of in vitro ﬁndings and for establishing causeand-effect relationships relevant to clinical observations,
which are typically correlative. We provide evidence that
animal-based studies have generated a durable framework
for dissecting the mechanistic basis of periodontitis. These
studies have solidiﬁed the etiologic role of bacteria in
initiating the inﬂammatory response that leads to periodontal
bone loss and have identiﬁed key mediators (IL-1, TNF,
prostaglandins,
complement,
RANKL)
that
induce
inﬂammatory breakdown. Moreover, animal studies suggest
that dysbiosis, rather than individual bacterial species, are
important in initiating periodontal bone loss and have
introduced the concept that organisms previously considered
commensals can play important roles as accessory pathogens
or pathobionts. These studies have also provided insight as to
how systemic conditions, such as diabetes or leukocyte
adhesion deﬁciency, contribute to tissue destruction. In
addition, animal studies have identiﬁed and been useful in
testing therapeutic targets.

Introduction
Animal models for the study of human disease have limitations that are inherent in the very definition of the term “model,”
i.e., an approximation or simulation of a real system that is under
investigation. It is thus obvious that no one single model reproduces all aspects of a human disease. However, the strengths of
animal models more than compensate for the simulation. First,
cause-and-effect relationships can be tested conclusively in animal models but are difficult to prove in human studies.
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Moreover, results from animal studies provide initial information
on the safety and potential efficacy of novel therapeutic compounds. Furthermore, animal models have less serious limitations
than in vitro models, which cannot replicate the complexity of
cross-interactions that occur between the immune response, the
microbiome, and the host tissue. The appropriateness of a given
animal model lies in its capacity to test a specific hypothesis
rather than its fidelity to all aspects of disease pathogenesis.
Therefore, different models of the same disease can be used to
test discrete aspects of its pathogenesis.1 In essence, animal models represent a point on a spectrum of assay systems that span the
more experimentally tractable in vitro models, through the biological complexity of animals, to clinically valid human studies
(Fig. 1).
The most common periodontitis models involve procedures
for oral gavage and placement of ligatures. The reader is referred
to previous publications for a detailed description of these models
and their successful application in a large number of studies.1-3
Briefly, in the oral gavage model, gingival inflammation and
bone loss can be induced following oral inoculation with bacteria
associated with human periodontitis. In the ligature-induced
periodontitis model, the placement of silk ligatures around posterior teeth facilitates local accumulation of indigenous bacteria
and enhances bacteria-mediated gingival inflammation and bone
loss. Although irrelevant for studying bone loss, the so-called
“chamber” and “abscess” models have been used to study specific
virulence aspects of periodontal organisms in vivo. In the chamber model, bacteria are injected into the lumen of a subcutaneously implanted titanium-coil chamber and in vivo bacterial
interactions with recruited inflammatory cells can be assessed
accurately and quantitatively.1,4,5 In the abscess model, bacteria
are injected subcutaneously into the dorsum and then scored for
impact on systemic health or localized abscess characteristics.6,7
It is now well established that periodontitis is triggered by
pathogenic microbial communities forming on subgingival tooth
surfaces while the host response is responsible for the tissue damage in periodontitis; moreover, systemic conditions have an
impact on periodontal disease by affecting pathologic mechanisms and host immune status.8,9 Animal studies have greatly
contributed to these critical principles which have been reproduced across several different animal species models demonstrating a consistency that lends support for the validity of the overall
concept, as well as the utility of animal models to study periodontal disease processes. The latter reflects the enduring usefulness of in vivo studies.
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Figure 1. Animal models of periodontitis: characteristics and contributions. Animal models are contrasted with in vitro models and human studies in
terms of their advantages and disadvantages, followed by a summary of key animal model-based contributions to understanding periodontal disease
pathogenesis. It should be noted, however, that animal model-based research beneﬁts from both in vitro models and human studies for obtaining mechanistic insights in ﬁner molecular detail and for determining clinical relevance, respectively. The cycle connecting the 3 experimental systems is meant to
demonstrate this interrelationship. For instance, the arrows emanating from “Animal models” and “Human studies” to “In vitro models” indicate the reliance of the former systems on the more tractable in vitro system for dissecting plausible molecular mechanisms. Conversely, the reverse arrows indicate
that in vitro model-based mechanisms depend on animal and human systems for testing potential biological relevance. One of the greatest contributions of animal models is the testing of cause-and-effect relationships that cannot be typically addressed in human studies, most of which are correlative.
Conversely, candidate drugs identiﬁed in animal models require the ultimate test in human clinical trials before they can be validated and enter the
clinic.

We will review studies that have provided a durable framework for understanding periodontal disease, as well as the most
common and important issues that have been raised over the
years with regard to the relevance of animal models, in particular
mice which are widely used in mechanistic studies. Moreover, we
will discuss whether these models maintain the potential to generate further knowledge for an in-depth understanding of periodontal disease pathogenesis.

The Role of Bacteria
The concept that bacteria are an important etiologic factor in
periodontal tissue destruction first came from studies of gnotobiotic rats and gnotobiotic mice.10,11 The role of bacteria was further demonstrated by topical application of antiseptics or
systemic application of antibiotics reducing bone loss in animal
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models involving dogs, mice, rats and non-human primates.12-15
The role of bacteria is further supported by findings that osteoclastogenesis and alveolar bone resorption are enhanced by the
application of bacteria.16,17 Thus loss of function (gnotobiotic
animals or use of anti-bacterials) and gain of function (the addition of bacteria) in a number of animal models (non-human primates, dogs, mice and rats) consistently establish a common role
of bacteria in initiating the disease process.
More recently, mouse models have additionally facilitated a
complete reappraisal of the role of certain organisms, such as
Streptococcus gordonii, which have traditionally been considered
as oral commensals. In vitro evidence indicates that S. gordonii
can contribute to community pathogenicity by providing an
attachment substratum for colonization by P. gingivalis.18 Hence
co-infection with S. gordonii and P. gingivalis in vivo would be
predicted to enhance both P. gingivalis colonization and alveolar
bone loss compared to monoinfection with P. gingivalis. Results

Virulence

Volume 6 Issue 3

from the oral gavage model support these predictions. Moreover,
blocking attachment of P. gingivalis to S. gordonii ameliorates
bone loss, thus opening a new avenue of research into therapeutic
agents in periodontal disease.19,20
In the murine abscess model, bacteria are delivered directly
into the animal without the need for specialized colonization factors and the alveolar bone is not involved. Despite the limited
applicability for periodontitis, the model does allow assessment
of an organism’s ability to resist immune killing, grow in vivo,
and spread systemically. A recent successful use of the abscess
model was to establish synergistic interactions between S. gordonii and Aggregatibacter actinomycetemcomitans. In vitro, growth of
A. actinomycetemcomitans is enhanced through utilization of Llactate produced as a metabolic by-product by S. gordonii.21 In
order for A. actinomycetemcomitans to cross-feed with S. gordonii,
it produces catalase by which it overcomes the adverse effects of
hydrogen peroxide released extracellularly by oral streptococci.
The murine abscess model not only confirmed the importance of
catalase but also established that dispersin B (DspB), an enzyme
that dissolves A. actinomycetemcomitans biofilms, is necessary for
nutritional synergism between A. actinomycetemcomitans and S.
gordonii.22 Specifically, 3D image analysis of the abscess material
revealed that DspB is required for an optimal spatial organization
of A. actinomycetemcomitans cells at >4 mm from S. gordonii cells,
a distance that minimizes exposure to peroxide but allows access
to L-lactate. Hence, provided the experimental questions are
framed to fit the model system, even a rudimentary model such
as abscess formation can provide valuable in vivo verification of
processes identified in vitro.
A potential issue regarding the use of mouse models to study
periodontal disease pathogenesis is that the periodontitis-associated
microbiotas in mice and humans differ considerably. However,
this is not a prohibitive factor for using mouse models since periodontitis is fundamentally a dysbiotic inflammatory disease precipitated by disruption of host-microbe homeostasis.9,23 Dysbiosis is
not dependent so much on the particular microbial roster but
rather on the specific gene combinations or collective virulence
activity within the altered microbial community.24,25 This notion
is supported by a recent metatranscriptomic study which showed
that disease-associated microbial communities exhibit conserved
metabolic and virulence gene expression profiles, despite high
inter-patient variability in terms of microbial composition.26
Therefore, a conserved periodontitis-associated microbiota is not a
requirement for the pathogenesis of human periodontitis. This
realization and the fact that periodontitis is not uniquely a human
disease27 and involves common pathogenic mechanisms among
different mammalian species (see above) validates the use of animal
models to study periodontitis. In a similar context, intestinal health
requires maintaining a balance between the colonic epithelium, the
immune system, and the resident microbiota, whereas the breakdown of this homeostatic relationship leads to inflammatory bowel
disease (IBD).28 As with periodontitis, this concept confers relevance to the use of mice as models for IBD pathogenesis despite
the differences between the mouse and human microbiotas.
Animal models can also provide insights into better understanding of data from human microbiome studies. A recent study
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in the murine oral gavage model has shown that the oral commensal microbiota is absolutely required for induction of inflammatory bone loss by P. gingivalis, which has traditionally been
considered a causative agent in human periodontitis.29 Such
commensals can act as pathobionts in a dysbiotic microbial community,30,31 and in human periodontitis are likely represented
by hitherto underappreciated species that have now been shown
to have as good or better a correlation with disease as P. gingivalis
(or other long-established pathogens).32-35 Therefore, a concept
first established in mice is consistent with and has explanatory
power for results obtained from metagenomic analyses of human
periodontitis. Moreover, the commensal-turned-pathobiont concept is supported by a recent metatranscriptomic study, which
revealed that a plethora of virulence factors upregulated in the
microbiome of periodontitis patients is primarily derived from
the previously underappreciated species that were not traditionally associated with periodontitis.36

The Role of the Host Immune Response
A controversy that has flared from time to time in the annals
of periodontal research involves the role of the host response in
periodontal destruction. That the host response and elements of
innate or adaptive immunity can be protective has been shown
by several studies. For instance, immunization of gnotobiotic rats
against P. gingivalis, protects against bone loss induced by inoculation of this bacterium37 as does immunization in non-human
primates and in mice.38-41 Similar results have been obtained by
adoptive transfer of T-helper lymphocytes.42 Moreover, both
humans and mice that fail to recruit neutrophils to the periodontal tissue (e.g., due to leukocyte-adhesion deficiency) develop an
aggressive form of periodontitis early in life.43 However, animal
models also provide conclusive evidence that the host response is
intimately involved in the destructive process. Both systemic and
topical application of non-steroidal anti-inflammatory drugs that
inhibit prostaglandin synthesis reduce periodontal bone loss in
spontaneously occurring periodontal disease in dogs and in ligature-induced periodontal disease in non-human primates.44,45
Similarly, application of factors that inhibit cytokines, including
tumor necrosis factor [TNF], interleukin [IL]-1, IL-17, complement, and RANKL reduce periodontal tissue destruction whether
induced by A. actinomycetemcomitans oral gavage or by ligatures
in mice or non-human primates, providing additional evidence
that the host response mediates bone loss.46-55 Moreover, such
studies have offered promising therapeutic targets for the treatment of human periodontitis. In contrast, application of IL-1 or
TNF, or genetic over-expression, enhances bone loss triggered by
bacteria.56-58 Likewise, attenuation of the host response by
genetic ablation generally lessens bacteria-induced bone loss.59-63
Thus, animal studies consistently demonstrate that bacteria alone
are not sufficient to induce periodontal bone loss, a conclusion
that would be difficult to make solely from in vitro studies or
human studies.
Recent studies have questioned the reliability of murine models for the investigation of human inflammatory disease, a broad
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conclusion which, if validated, would have a significant impact
on the use of mouse models of periodontal disease. Specifically,
gene expression profiling of C57BL/6J mice and humans during
endotoxemia revealed poor correlation between the human genes
and mouse orthologues and vice versa.64 However, this shortcoming in fact does not apply to periodontitis where the same
inflammatory mediators (e.g., prostaglandin E2, TNF, IL-1b,
and IL-17) mediate inflammatory bone loss in various species
including mice, rats, dogs, non-human primates, and
humans.43,46,54,55,63,65-68 Moreover, important innate or adaptive immune players implicated in experimental mouse periodontitis have been confirmed in higher animals. For instance the
central complement component C3 promotes inflammatory periodontal bone loss in both mice and non-human primates,55
whereas regulatory T cells mediate protection against the same
condition in both mice and dogs.67
When mouse models are used in an appropriate context to
address specific hypotheses in periodontal disease pathogenesis,
the results obtained have been consistent with in vitro observations using human cells. For instance, studies in the oral gavage
model have confirmed the capacity of P. gingivalis to inhibit the
expression of E-selectin and neutrophil-recruiting chemokines,29
as predicted by the local chemokine paralysis model first established in vitro using endothelial and gingival epithelial cells.69,70
Moreover, consistent with the requirement of intact C5a receptor
(C5aR) signaling in human leukocytes for successful evasion of
killing by P. gingivalis, the organism fails to colonize the periodontium of C5aR-deficient mice, in contrast to wild-type mice
where P. gingivalis can persist and cause disease.29,71,72 Moreover,
local treatment of P. gingivalis-colonized mice with a C5aR
antagonist essentially eliminates P. gingivalis, reverses its dysbiotic effect, and inhibits development of periodontitis.29,71,73 In
line with in vitro evidence that P. gingivalis can escape TLR4 recognition or activation,74 TLR4-deficient neutrophils display normal inflammatory responses to P. gingivalis in the chamber
model, comparable with wild-type neutrophils (but not TLR2deficient neutrophils which exhibit a poor response).5 Furthermore, the lipid A phosphatase activity of P. gingivalis, which is
required for modulation of lipid A structure and hence evasion of
TLR4,74 was shown to contribute to the capacity of P. gingivalis
for oral colonization and enhancement of the commensal bacterial load in a rabbit model of ligature-induced periodontitis.75
These studies also justify the characterization of P. gingivalis as a
keystone pathogen, a concept that is relevant also in other inflammatory dysbiotic diseases.76,77 The consistency between in vivo
animal and in vitro human experimental systems not only confers
biological significance to the in vitro findings but also lends further support and validation of these animal models.
One potential limitation of rodent models is that the cells and
effector molecules of the immune system can differ from their
human counterparts as is the case with the neutrophil chemokine
CXCL8/IL-8. Mice and rats do not produce IL-8, but they do
produce functionally equivalent homologs that are controlled by
the transcription factor NF-kB.78-80 P. gingivalis can inhibit neutrophil transmigration toward human epithelial cells in vitro81
through production of a serine phosphatase, SerB, that inhibits
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NF-kB activation by dephosphorylating its p65 subunit.69,70 An
important test of the relevance of rodent models then was to
assess the functionality of SerB in vivo. In the rat oral gavage
model, a SerB-deficient mutant of P. gingivalis incited greater
neutrophil infiltration in gingival tissues.82 Thus, even though
specific immune effectors may differ between rodents and
humans, similarity in the command and control pathways
ensures that mice and rats can indeed model the human immune
systems in many important ways.
In addition to inducing periodontitis via oral gavage or ligature placement, the disease can develop in mice spontaneously as
a result of the aging process, a factor that also contributes to
human periodontitis.83 The use of the aging-associated periodontitis model led to the identification of a novel molecule involved
in periodontal tissue homeostasis, namely the endothelial cellderived glycoprotein Del-1.54 Del-1 engages in reciprocal antagonistic interactions with IL-17 in terms of their expression and
function in neutrophil recruitment and inflammation. This
reciprocal relationship has been confirmed in humans, with Del1 dominating in healthy gingiva and IL-17 prevailing in inflamed
gingiva.54
Importantly, the induction of periodontitis in mice involves
more physiological means as compared to other widely used
mouse models of other human diseases. For instance, chemicallyinduced models of IBD have limitations in understanding events
that initiate gut inflammation in human IBD.84 Psoriasis, a Tcell-mediated chronic inflammatory skin disease, is generally not
seen in animals other than humans, yet, various mouse models
including transgenics and knockouts have been developed that
mimic psoriasis.85 Despite their serious limitations, these models
have established that psoriasis is a T-cell-mediated disease and
have been used to dissect novel pathways of disease pathogenesis.
In experimental autoimmune encephalomyelitis, a model of
human multiple sclerosis, the disease is often induced artificially
after injection of autoantigen emulsified in complete Freund’s
adjuvant. This promotes the induction of CD4C T cell-mediated
autoimmune mechanisms, whereas CD8C T cells prevail in multiple sclerosis lesions.86 Similarly, collagen-induced arthritis in
mice, a commonly used model of rheumatoid arthritis, is elicited
by immunization with type II collagen formulated in complete
Freund’s adjuvant.87 Nevertheless, imperfect as they may be,
these models have significantly enhanced our understanding of
disease pathogenesis.

Impact of Systemic Disease
It is well documented in human studies that systemic conditions such as diabetes mellitus increase the risk and severity of
periodontal disease.88 Animal models have established a mechanistic basis for this phenomenon. Both type 1 and type 2 diabetic
mice exhibit a greater inflammatory response than normal mice
to the same inoculation of P. gingivalis into connective tissue.89,90 If TNF is blocked in diabetic rats or diabetic mice,
much of the diabetes-enhanced bone resorption is reversed, indicating that diabetes-enhanced inflammation, particularly TNF, is
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problematic.91-93 Interestingly, diabetes appears to cause a particular problem in the resolution of inflammation which leads to
dysregulation of a number of pathways that both enhance bone
resorption and reduce coupled bone formation.94,95 A number of
factors may enhance inflammation in diabetic animals including
increased formation of advanced glycation end products
(AGEs).8 When AGE signaling is blocked in a periodontal disease model both diabetes-enhanced TNF levels and periodontal
bone loss are reduced.96 Therefore, human studies have provided
evidence of an association between diabetes, AGEs, inflammation
and periodontal disease, but animal studies with the use of specific inhibitors provide conclusive evidence of functional relationships between these parameters and identify specific processes
affected. Conversely, the notion that periodontitis exerts an
adverse impact on systemic health is substantiated by mechanistic
animal studies linking periodontitis or periodontal pathogens to
disorders such as atherosclerosis, adverse pregnancy outcomes,
and rheumatoid arthritis.97,98

Conclusion
In summary, whereas no one animal model can recapitulate
the complexity of periodontal disease, different aspects of the disease can be represented by different models, which have contributed considerably in dissecting the mechanistic underpinning of
periodontitis. Of course, the synthesis and integration of findings
from all available experimental systems (in vitro, animal, human)
are required for better understanding of disease pathogenesis
(Fig. 1). A good example of the interconnectivity and relevance
of each experimental system is provided by the treatment of periodontitis with local delivery of tetracyclines. Tetracyclines have
been shown to inhibit periodontal disease in rats and to alter the
subgingival microflora in humans.15,99 However, experiments
with germ-free rats demonstrated that tetracyclines can reduce
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